Osman Ratib, MD, PhD, FAHA, professor and chief of nuclear medicine in the Department of Radiology at the University Hospital of Geneva, discusses the advantages and future of the hybrid PET/MR modality.
[[{"type":"media","view_mode":"media_crop","fid":"8165","attributes":{"alt":"","class":"media-image media-image-left","id":"media_crop_9348676445430","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"213","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"margin: 5px; float: left;","title":" ","typeof":"foaf:Image"}}]] Bridging the two complementary modalities of PET and MR has advantages over PET/CT, as a lower dose and more differentiating modality. That's according to Osman Ratib, MD, PhD, FAHA, professor and chief of nuclear medicine in the Department of Radiology and chairman of the Department of Imaging and Medical Informatics at the University Hospital of Geneva. His orgnanization was an early adopter of PET/MR with Philips’ Ingenuity TF, which received FDA clearance in November 2011.
The system includes two devices separated by about 10 feet with a rotating table so the patient can be scanned in the same position in each machine. Data are merged via software. In this podcast, Ratib discusses the advantages of this hybrid modality, what the transition was like for hospital staff, and the future of PET/MR.
[[{"type":"media","view_mode":"media_crop","fid":"11969","attributes":{"alt":"","class":"media-image","id":"media_crop_8968679564714","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"214","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image"}}]]
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.